Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers

The latest immunotherapy, used in the treatment of non-small cell lung cancer (NSCLC), uses monoclonal antibodies directed against programmed death ligand 1 (PD-L1) to inhibit its interaction with the PD-1 receptor. Elevated levels of PD-L1 expression were observed on NSCLC cells. The association be...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2019-02, Vol.20 (4), p.824
Main Authors: Pawelczyk, Konrad, Piotrowska, Aleksandra, Ciesielska, Urszula, Jablonska, Karolina, Gletzel-Plucinska, Natalia, Grzegrzolka, Jedrzej, Podhorska-Okolow, Marzenna, Dziegiel, Piotr, Nowinska, Katarzyna
Format: Article
Language:English
Subjects:
Antigens
Apoptosis
Breast
Colon
Diagnostic systems
Fatalities
Immunoglobulins
Immunotherapy
Ki-67
Ligands
Lung cancer
Lymphatic system
Lymphocytes
Medical prognosis
Metastasis
Necrosis
non-small cell lung cancer
Non-small cell lung carcinoma
p63
PD-L1
PD-L1 protein
Prostate
Prostate cancer
Protein expression
Proteins
T cell receptors
TTF-1
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The latest immunotherapy, used in the treatment of non-small cell lung cancer (NSCLC), uses monoclonal antibodies directed against programmed death ligand 1 (PD-L1) to inhibit its interaction with the PD-1 receptor. Elevated levels of PD-L1 expression were observed on NSCLC cells. The association between PD-L1 expression and clinicopathological features is still unclear. Therefore, we examined this relationship and also compare PD-L1 expression levels with Ki-67, p63 and TTF-1. 866 samples of NSCLCs were used to prepare tissue microarrays (TMAs) on which immunohistochemical (IHC) reactions were performed. Changes in the level of ( ) gene expression in 62 NSCLC tumors were tested in relation to 14 normal lung tissues by real-time PCR reactions (RT-PCR). PD-L1 expression was observed in 32.6% of NSCLCs. PD-L1 expression was increased in higher malignancy grades (G) ( < 0.0001) and in higher lymph node status (pN) ( = 0.0428). The patients with low PD-L1 expression had longer overall survival compared to the group with high expression ( = 0.0332) in adenocarcinoma (AC) only. PD-L1 expression seems to be associated with increased tumor proliferation and aggressiveness as well as shorter patient survival in NSCLC, predominantly in the AC group.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms20040824